Business Information
The group's principal activity is to acquire, develop and commercialize innovative products for the treatment of hematology and oncology patients. The group has established their own regulatory, development and sales and marketing organizations covering the U.S., Europe and Australia. It also has established third party distributor network to serve the hematology and oncology markets in 20 additional countries throughout the Middle East and Asia. The products of the group are innohep(R), refludan(R), thalidomide pharmion 50mgtm and vidazatm. The products are sold to wholesale distributors and directly to hospitals, clinics, and retail pharmacies. On 25-Mar- 2003, the group acquired laphal development s.a and gophar s.a.s.
|
|
Name |
Title
|
Email
|
| Grant Prentice | Chmn. - Scientific Advisor | N/A | | Andrew Allen | Chief Medical Officer, Exec. VP | N/A | | Erle Mast | CFO, Exec. VP | N/A | | Gillian Ivers-Read | Exec. VP - Development Operations | N/A | | Jay Backstrom | VP - Global Medical, Safety | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 238,646 | (91,012) | | 2005 | 221,244 | 2,269 | | 2004 | 130,171 | (17,537)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
